louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02122276: Effects of Continuous Passive Motion on the Spinal Circuitries and Its Adaptation in Patients With Spasticity Resulting From Upper Motor Neuron Lesions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Spinal Cord Injury(SCI)
Keywords: Spinal cord injury
Passive motion
Fatigue index
Hypertonia
Lead sponsor: Chang Gung University
Sponsor class: OTHER
First posted: 2014-04-24
Enrollment: 7
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: In animal and human studies, histochemical and physiological evidences showed that the muscle transferred from slow, fatigue-resistant muscle to fast, fatigable muscle after spinal cord injury. The alternation of muscular property was accompanied by the alternation of spinal circuitry property, and was related to the immobilization adaptation. Previous study showed that remobilization by continuous passive motion (CPM) for one month would restore the function of spinal circuitry in individual with chronic SCI. It is possible that long term application of CPM can reverse the adaptation of contractile properties of the paralyzed muscle after SCI. The purpose of this study is to investigate the effect of a four month CPM training on muscular properties in individuals with chronic SCI.


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of complete spinal cord injury

Primary outcomes:
measure: The contractile properties of the muscles
timeFrame: Baseline, 1 month, 2 months, 3 months, and 4 months
measure: Fatigue index
timeFrame: Baseline, 1 month, 2 months, 3 months, and 4 months
measure: Clinical muscle tone tests
timeFrame: Baseline, 1 month, 2 months, 3 months, and 4 months
measure: Patient Reported Impact of Spasticity Measure (PRISM)
timeFrame: Baseline, 1 month, 2 months, 3 months, and 4 months
measure: The potential adverse effects of ankle swelling
timeFrame: Baseline, 1 month, 2 months, 3 months, and 4 months
Secondary outcomes:
Other outcomes:
Locations:
city: Taoyuan
country: Taiwan
facility: Chang Gung University
Study officials:
References:
Clinical trial NCT04480476: A Retrospective, Natural History Study in Children With CLN2
Official title: A Retrospective, Chart Review Study to Evaluate Ocular Disease Progression in Children With Late-infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2)
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Late-infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2)
Keywords: CLN2, Batten Disease
Lead sponsor: REGENXBIO Inc.
Sponsor class: INDUSTRY
First posted: 2020-07-21
Enrollment: 0
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with CLN2 Batten Disease

Brief summary: This is a multi center, retrospective, chart review study to document the evolution of ocular disease progression in pediatric patients with CLN2.

Detailed description: CLN2 is a rare disease with limited available ocular natural history data. While current standard of care slows motor degeneration, it is not known to treat the ocular manifestations of disease. This study is planned to document, through retrospective data collection, ocular disease progression in children with a clinical presentation consistent with CLN2. No investigational product is administered in this retrospective, chart review study.

Eligibility criteria: Inclusion Criteria:

A participant is eligible to be included in the study only if all of the following criteria apply:

1. The participant's legal guardian(s) is(are) willing and able to provide them written, signed informed consent.
2. The participant has a documented diagnosis of CLN2 disease due to TPP1 deficiency, or has a relative clinically diagnosed with CLN2 disease who has the same CLN2 mutations as the participant
3. The participant has had one or more eye examinations by an eye care specialist at any time since birth.

Exclusion Criteria:

No exclusion criteria apply to this study.

Primary outcomes:
measure: Characterize retinal structural changes in children with CLN2
timeFrame: From first available medical chart through informed consent, an average of 10 years
Secondary outcomes:
measure: Characterize changes in visual function.
timeFrame: From first available medical chart through informed consent, an average of 10 years
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05250076: Immediate Effects of Kinesio Tape on Median Nerve's Mechanosensitivity
Official title: Immediate Effects of Kinesio Tape on Median Nerve's Mechanosensitivity, Measured by the Upper Limb Neurodynamic Test 1 (ULNT1) in Healthy Participants: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Lead sponsor: University Fernando Pessoa
Sponsor class: OTHER
First posted: 2022-02-22
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The purpose of this study is to verify the immediate effects of Kinesio Tape on median nerve's mechanosensitivity, measured by the upper limb neurodynamic test 1 (ULNT1) in healthy participants.

Detailed description: After completing the socio-demographic and clinical questionnaire, the participants will be randomly assigned into two designated groups, the Intervention Group (IG; n = 30) (Kinesio tape throughout the median nerve course) and the Control Group (CG; n = 30) (remained at rest for 5 minutes), using the software www.graphpad.com/quickcals.

Eligibility criteria: Inclusion Criteria:

* Healthy university students of both genders with normal mobility of the joints of the upper quadrant of the body

Exclusion Criteria:

* Deformities in the upper quadrant region of the body;

  * Complaints in this region in the last 6 months;
  * Surgical procedures or musculoskeletal, cardiac, renal, metabolic, neurological and or oncological pathologies of the upper quadrant that may disturb nerve function;
  * Not present any mechanosensitive response to ULNT1;
  * Pregnant women;
  * Ingestion of non-steroidal anti-inflammatory drugs or consumption of any type of narcotic drugs and participants who have drunk alcohol in the last 12 hours.

Primary outcomes:
measure: change in elbow extension range of motion measured by smartphone
timeFrame: [Time Frame: Baseline (Moment 0), Immediately after intervention or control (Moment 1) .]]
Secondary outcomes:
Other outcomes:
Locations:
city: Porto
country: Portugal
facility: Ricardo Cardoso
Study officials:
affiliation: Fernando Pessoa University
name: Ricardo Cardoso, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01136876: Kidney Damage in Patients With Moderate Fall in eGFR
Official title: Pilot Study to Evaluate Kidney Damage Measured by Neutrophil Gelatinase-Associated Lipocalin as New Biomarker in Patients With Moderate Fall in eGFR Undergoing Percutaneous Coronary Intervention With IOPAMIDOL Injection 370 or IODIXANOL 320
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Coronary Artery Stenosis
Lead sponsor: Bracco Diagnostics, Inc
Sponsor class: INDUSTRY
First posted: 2010-06-04
Enrollment: 57
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: To compare Iopamidol injection 370 and Iodixanol 320 in evaluating Neutrophil Gelatinase-Associated Lipocalin (NGAL) in patients with moderate fall in eGFR

Detailed description: This is a pilot study having a randomized, double-blind parallel group comparison of two iodinated contrast agents used during percutaneous coronary intervention (PCI). All patients enrolled must have eGFR greater than or equal to 30 mL/min and less than or equal to 59 mL/min. Statistical summaries will be presented to analyze the various lab tests results for the two groups.

Eligibility criteria: Inclusion Criteria:

* At least 18 years of age and provides informed consent
* Scheduled to undergo percutaneous coronary intervention
* Documented pre-dose Estimated glomerular filtration rate (eGFR) of greater than or equal to 30 mL/min/1.73 m squared and less than or equal to 59 mL/min/1.73 m squared

Exclusion Criteria:

* Pregnant or lactating females
* Severe congestive heart failure
* History of hyperthyroidism;
* Unstable renal function
* Emergency PCI
* History of hypersensitivity to iodinated contrast agents
* Receiving diuretics to prevent acute renal injury

Primary outcomes:
measure: Impact on the Trajectory of Serum and Urinary Neutrophil Gelatinase-associated Lipocalin (NGAL) Following Administration
timeFrame: Baseline and 2, 4, 6, 24, 48,and 72 hours post-dose
Secondary outcomes:
Other outcomes:
Locations:
city: Springfield
country: United States
facility: Research Cooperative, St. John's Hospital
state: Illinois
city: New Brunswick
country: United States
facility: UMDNJ - RWJ Medical School
state: New Jersey
city: Teaneck
country: United States
facility: The Institute for Clinical Research at Holy Name Medical Center
state: New Jersey
city: Montréal
country: Canada
facility: Montreal Heart Institute
state: Quebec
Study officials:
affiliation: Bracco Diagnostics, Inc
name: Maria Luigia Storto, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT05357976: The Effects of Body Mass Index on Thoracic Paravertebral Block Analgesia
Official title: The Effects of Body Mass Index on Thoracic Paravertebral Block Analgesia Treatment in Patients Undergoing Thoracoscopic Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pain, Postoperative
Acute Pain
Thoracic Paravertebral Block
Body Mass Index
Thoracic Surgery, Video-Assisted
Lead sponsor: Ankara City Hospital Bilkent
Sponsor class: OTHER
First posted: 2022-05-03
Enrollment: 75
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Obesity has become one of the world's leading health problems. It is known that obesity causes many diseases and negatively affects the quality of life. For this reason, many conditions that are thought to be effective in obesity and concern the quality of life of patients have been scientifically researched and continue to be investigated. One of them is postoperative pain. Although there are studies stating that there is no relationship between body mass index (BMI) and postoperative pain, when the literature data is examined, it is thought that obesity is a risk factor for postoperative pain and changes pain sensitivity and analgesic needs of patients. There are also studies in the literature stating that the level of postoperative pain increases in parallel with each unit increase in BMI.

After thoracic surgery, many analgesic methods have been suggested, including thoracic epidural analgesia (TEA), thoracic paravertebral block (TPVB), intercostal nerve blocks (ICSB), erector spina plane block (ESPB), serratus anterior plane block (SAPB). This study will compare the effects of BMI on postoperative pain in patients undergoing TPVB for postoperative analgesia and thoracoscopic surgery.


Eligibility criteria: Inclusion Criteria:

* 18 to 80 years old
* ASA physical status I-II-III
* BMI 18 to 40 kg/m2
* Elective video-assisted thoracoscopic surgery

Exclusion Criteria:

* Patient refusing the procedure
* Emergency surgery
* Chronic opioid or analgesic use
* Patients who will operate under emergency conditions
* Patients who will not undergo VATS

Primary outcomes:
measure: Pain Scores
timeFrame: 1st hour after surgery.
measure: Pain Scores
timeFrame: 2nd-hour after surgery.
measure: Pain Scores
timeFrame: 4th-hour after surgery.
measure: Pain Scores
timeFrame: 12th-hour after surgery.
measure: Pain Scores
timeFrame: 24th-hour after surgery.
measure: Pain Scores
timeFrame: 48th-hour after surgery.
Secondary outcomes:
measure: Morphine Consumption
timeFrame: 24 hours after surgery
Other outcomes:
Locations:
city: Keçiören
country: Turkey
facility: Ankara Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital
state: Ankara
city: Çankaya
country: Turkey
facility: Ankara City Hospital
state: Ankara
Study officials:
affiliation: Ankara City Hospital Bilkent
name: Nilgün Zengin, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01093027: Electrophysiological Study of the Effects of Limb Cooling on Essential Tremor
Official title: Electrophysiological Study of the Effects of Limb Cooling on Essential Tremor
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Tremor
Keywords: Essential Tremor
Cooling
Temperature
Patients with Essential Tremor involving the upper limbs with at least moderate tremor.
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2010-03-25
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 95
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: To determine the effects of upper limb forearm cooling on Essential Tremor upper limb tremor using a more practical method of limb cooling through a forearm cold pack.


Eligibility criteria: Inclusion Criteria:

* Patients with clinical diagnosis of E.T. for at least a year by a movement disorder neurologist
* A +2 or worse action or kinetic tremor of one or both upper limbs involving at least the forearm and/or hand
* Ages 18 to 95 years old

Exclusion Criteria:

* (+) sensory loss in the upper extremities
* dermatologic lesions in upper extremities (e.g. skin cancer, eczema, fresh or healing wounds, abrasions, acne, pustules, abscesses, or skin rash)
* known history of sensitivity to cold (i.e., cold urticaria)
* known peripheral vascular disease
* Raynaud's phenomenon
* scleroderma

Primary outcomes:
measure: Tremor Amplitude
timeFrame: After 10 minutes of limb cooling treatment.
Secondary outcomes:
measure: Tremor Rating Scale
timeFrame: After 10 minutes of limb cooling treatment.
Other outcomes:
Locations:
city: Scottsdale
country: United States
facility: Mayo Clinic Arizona
state: Arizona
Study officials:
affiliation: Mayo Clinic
name: Virgilio Evidente, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03479827: Measuring the Peripheral Optical Quality of The Eye
Official title: Measuring the Peripheral Optical Quality of The Eye
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Nearsightedness
Lead sponsor: University of Rochester
Sponsor class: OTHER
First posted: 2018-03-27
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults with no ocular pathology and uses contact lenses.

Brief summary: The goal of the study is to quantify wavefront aberration profiles of the eye with and without contact lens across the visual field. This will enable us to investigate the impact of the aberration on retinal image quality.

Detailed description: The goal of this study is to investigate the effects of monofocal and bifocal soft contact lenses in the changes of peripheral optical quality and through-focus visual performance on real eyes. The goal will be accomplished by performing optical measurements using Shack-Hartmann wavefront sensor with and without the use of single vision and bifocal soft contact lenses.

Eligibility criteria: Inclusion Criteria

A person will be included in the study if he/she:

* Is 18 years or older and has full legal capacity to volunteer.
* Has no ocular condition or pathology, which may impact visual acuity e.g. keratoconus, amblyopia, cataract, macular degeneration;
* Has no active ocular disease or allergic conjunctivitis;
* Is not using any topical ocular medications;
* Is willing and able to follow instructions;
* Has voluntarily agreed to participate in the study by signing the statement of informed consent.

Exclusion Criteria

A person will be excluded from the study if he/she:

* Is under the age of 18 or over the age of 60 yrs.
* Correctable with high contrast logMAR acuity (EDTRS) testing to 20/20 or better;
* Pregnant at the time of enrolment in the study;
* Unable to handle, insert, remove or care for the study lenses;
* Considered by the Investigator to not be a suitable candidate for participation.

Primary outcomes:
measure: Mean Wavefront aberrations
timeFrame: less than 2 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: University of Rochester
state: New York
Study officials:
affiliation: University of Rochester
name: Geunyoung Yoon, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03509727: Procalcitonin in Diagnosis of Bacterial Infections in Young Infants
Official title: Point-of-care-testing for Procalcitonin in Diagnosis of Bacterial Infections in Young Infants: a Diagnostic Accuracy Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sepsis
Lead sponsor: Belfast Health and Social Care Trust
Sponsor class: OTHER
First posted: 2018-04-26
Enrollment: 126
Sex: ALL
Maximum age (years): 90
Standard ages: CHILD
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All young infants presenting to the emergency department with suspected infection are eligible for testing.

Brief summary: A diagnostic accuracy study investigating the accuracy of procalcitonin in diagnosing invasive bacterial infections in your infants.

Detailed description: The primary aim of this study was to report on the diagnostic accuracy of procalcitonin in the diagnosis of bacterial infections in young infants. This included invasive bacterial infections; defined as the isolation of a bacterial pathogen in blood or cerebrospinal fluid culture.

We conducted a prospective observational diagnostic accuracy study. Young infants less than 90 days of age presenting to the Royal Belfast Hospital for Sick Children with signs of possible bacterial infection were eligible for inclusion. Eligible infants underwent procalcitonin testing using 0.5ml of whole blood with a BRAHMS assay on the Samsung LABGEO IB10® analyser.

Eligibility criteria: Inclusion Criteria:

* Suspected bacterial infection

Exclusion Criteria:

* None

Primary outcomes:
measure: Invasive bacterial infection
timeFrame: 2 days
Secondary outcomes:
Other outcomes:
Locations:
city: Belfast
country: United Kingdom
facility: Royal Belfast Hopsital for Sick Children
Study officials:
affiliation: Queen's University, Belfast
name: Michael Shields
role: PRINCIPAL_INVESTIGATOR
References:
citation: Waterfield T, Maney JA, Hanna M, Fairley D, Shields MD. Point-of-care testing for procalcitonin in identifying bacterial infections in young infants: a diagnostic accuracy study. BMC Pediatr. 2018 Dec 12;18(1):387. doi: 10.1186/s12887-018-1349-7.
Clinical trial NCT04688827: Impact of Additional Resistance Training During Rehabilitation Therapy in Patients With Heart Failure
Official title: Impact of Different Types of Resistance Training Additional to Endurance Training During Rehabilitation Therapy in Patients With Heart Failure
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Heart Failure
Keywords: heart failure
resistance training
rehabilitation therapy
Lead sponsor: Hasselt University
Sponsor class: OTHER
Collaborators: name: Ziekenhuis Oost-Limburg
First posted: 2020-12-30
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The impact of moderate- or low-intensity resistance training will be investigated additional to endurance training in heart failure patients following rehabilitation. The aim is to optimize intensity of resistance training in this patient population.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of heart failure and participation in cardiac rehabilitation

Exclusion Criteria:

* Orthopedic disorders, neurological disorders affecting muscle strength, cognitive disorders, heart or arterial surgery (percutaneous coronary intervention, bypass, heart valve surgery) in the last year, acute myocardial infarction in the last 6 months, participation in another intervention

Primary outcomes:
measure: VO2peak
timeFrame: Prior to the intervention
measure: VO2peak
timeFrame: After 15 weeks of intervention
measure: VO2peak
timeFrame: After 24 weeks of follow-up
Secondary outcomes:
measure: Muscle strength
timeFrame: Prior to the intervention
measure: Muscle strength
timeFrame: After 15 weeks of intervention
measure: Muscle strength
timeFrame: After 24 weeks of follow-up
measure: Functional capacity
timeFrame: Prior to the intervention
measure: Functional capacity
timeFrame: After 15 weeks of intervention
measure: Functional capacity
timeFrame: After 24 weeks of follow-up
measure: Quality of life in heart failure patients
timeFrame: Prior to the intervention
measure: Quality of life in heart failure patients
timeFrame: After 15 weeks of intervention
measure: Quality of life in heart failure patients
timeFrame: After 24 weeks of follow-up
measure: Cardiac function
timeFrame: Prior to the intervention
measure: Cardiac function
timeFrame: After 15 weeks of intervention
measure: Cardiac function
timeFrame: After 24 weeks of follow-up
measure: Anthropometric measurements
timeFrame: Prior to the intervention
measure: Anthropometric measurements
timeFrame: After 15 weeks of intervention
measure: Anthropometric measurements
timeFrame: After 24 weeks of follow-up
Other outcomes:
Locations:
city: Genk
country: Belgium
facility: Ziekenhuis Oost-Limburg
state: Limburg
Study officials:
References: